Candel Therapeutics, Inc.
CADL
$4.79
$0.030.63%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -26.84% | -26.21% | -131.30% | 6.53% | -118.28% |
| Total Depreciation and Amortization | -1.61% | 0.00% | 5.51% | 9.13% | 12.67% |
| Total Amortization of Deferred Charges | -39.53% | -25.30% | -7.59% | 10.67% | 7.50% |
| Total Other Non-Cash Items | 314.65% | 718.49% | 2,169.84% | 581.33% | 185.68% |
| Change in Net Operating Assets | -53.48% | 179.77% | -69.18% | 32.59% | 2,349.30% |
| Cash from Operations | 21.67% | 25.37% | 13.86% | 22.01% | -7.80% |
| Capital Expenditure | 93.62% | 100.00% | 96.45% | 94.93% | 82.97% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 88.89% | 100.00% | 96.45% | -136.84% | 90.22% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 76,061.16% | -- | -- | -- | -436.11% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,237.33% | 45.06% | 42.16% | 10.19% | -6.25% |